Evidence map›Paper›PMID 35244717›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2022

Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.

Alexander N Comninos, Morten S Hansen, Alan Courtney, Sirazum Choudhury, Lisa Yang, Edouard G Mills, Maria Phylactou, Mark Busbridge, Muaza Khir, Thilipan Thaventhiran and 5 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.The Journal of clinical endocrinology and metabolism · 2022
    Trial
  4. Review
  5. Review
  6. Review
  7. Crosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Alexander N ComninosDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.ORCID 0000-0002-7104-2297
Morten S HansenKMEB Molecular Endocrinology Laboratory, Department of Endocrinology, Odense University Hospital, Denmark.
Alan CourtneyDepartment of Clinical Biochemistry, Imperial College Healthcare NHS Trust, London, UK.
Sirazum ChoudhuryDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.ORCID 0000-0003-2429-005X
Lisa YangDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Edouard G MillsDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Maria PhylactouDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Mark BusbridgeDepartment of Clinical Biochemistry, Imperial College Healthcare NHS Trust, London, UK.
Muaza KhirDepartment of Clinical Biochemistry, Imperial College Healthcare NHS Trust, London, UK.
Thilipan ThaventhiranDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Paul BechDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Tricia TanDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.ORCID 0000-0001-5873-3432
Ali AbbaraDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.ORCID 0000-0003-2795-5256
Morten FrostKMEB Molecular Endocrinology Laboratory, Department of Endocrinology, Odense University Hospital, Denmark.
Waljit S DhilloDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.ORCID 0000-0001-5950-4316
Imperial College Healthcare NHS Trust · GBImperial College London · GBSteno Diabetes Centers · DKUniversity of Southern Denmark · DK

Funding

Medical Research Council MR/R000484/1Medical Research Council MR/T006242/1MRC MR/R000484/1NIHR
6 · The paper itself

Abstract

contextOsteoporosis results from disturbances in bone formation and resorption. Recent nonhuman data suggest that the reproductive hormone kisspeptin directly stimulates osteoblast differentiation in vitro and thus could have clinical therapeutic potential. However, the effects of kisspeptin on human bone metabolism are currently unknown.

objectiveTo assess the effects of kisspeptin on human bone metabolism in vitro and in vivo.

methodsIn vitro study: of Mono- and cocultures of human osteoblasts and osteoclasts treated with kisspeptin. Clinical study: Randomized, placebo-controlled, double-blind, 2-way crossover clinical study in 26 men investigating the effects of acute kisspeptin administration (90 minutes) on human bone metabolism, with blood sampling every 30 minutes to +90 minutes. Cells for the in vitro study were from 12 male blood donors and 8 patients undergoing hip replacement surgery. Twenty-six healthy eugonadal men (age 26.8 ± 5.8 years) were included in the clinical study. The intervention was Kisspeptin (vs placebo) administration. The main outcome measures were changes in bone parameters and turnover markers.

resultsIncubation with kisspeptin in vitro increased alkaline phosphatase levels in human bone marrow mesenchymal stem cells by 41.1% (P = .0022), and robustly inhibited osteoclastic resorptive activity by up to 53.4% (P < .0001), in a dose-dependent manner. Kisspeptin administration to healthy men increased osteoblast activity, as evidenced by a 20.3% maximal increase in total osteocalcin (P = .021) and 24.3% maximal increase in carboxylated osteocalcin levels (P = .014).

conclusionCollectively, these data provide the first human evidence that kisspeptin promotes osteogenic differentiation of osteoblast progenitors and inhibits bone resorption in vitro. Furthermore, kisspeptin acutely increases the bone formation marker osteocalcin but not resorption markers in healthy men, independent of downstream sex steroid levels. Kisspeptin could therefore have clinical therapeutic application in the treatment of osteoporosis.

Indexed as

Bone ResorptionOsteoporosisAdultCell DifferentiationHumansKisspeptinsMaleOsteoblastsOsteocalcinOsteogenesisYoung AdultKisspeptinsOsteocalcinbone metabolismkisspeptinosteoporosisreproduction

Identifiers

PMID35244717
PMCPMC9113799
OpenAlexW4214874467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.